Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain SUPN message board posts where the ticker symbol SUPN has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

Related news from
Wed, 06 Mar 2024
21:30:00 +0000
Supernus to Participate in Two Upcoming Investor Conferences
ROCKVILLE, Md., March 06, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in the following March investor conferences: Jefferies Biotech on the Bay SummitDate:Tuesday, March 12, 2024Place:The 1 Hotel South Beach, Miami, Fla. Barclays Glob
Tue, 05 Mar 2024
01:28:43 +0000
11 Best Small Cap Pharma Stocks to Invest In
In this piece, we will take a look at the 11 best small cap pharma stocks to invest in. If you want to skip our overview of the global pharmaceutical and healthcare industry, which is one the most unique sectors in the world, then you can check out 5 Best Small Cap Pharma Stocks to […]
Thu, 29 Feb 2024
11:39:58 +0000
Supernus Pharmaceuticals Full Year 2023 Earnings: Beats Expectations
Supernus Pharmaceuticals ( NASDAQ:SUPN ) Full Year 2023 Results Key Financial Results Revenue: US$607.5m (down 8.9...
Wed, 28 Feb 2024
21:30:00 +0000
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
ROCKVILLE, Md., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack Khattar, President and CEO of Supernus Pharmaceuticals, will participate in a fireside chat at the TD Cowen 44th Annual Healthcare Conference on Wednesday, March 6, 2024, at 9:10 a.m. ET at the Marriott Copley Place in Boston, Mass. Inves
Wed, 28 Feb 2024
14:19:30 +0000
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2023 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2023 Earnings Call Transcript February 27, 2024 Supernus Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to the Supernus Pharmaceuticals’ Fourth Quarter and Full Year 2023 Financial Results Conference […]
Wed, 28 Feb 2024
12:17:15 +0000
Q4 2023 Supernus Pharmaceuticals Inc Earnings Call
Q4 2023 Supernus Pharmaceuticals Inc Earnings Call
Wed, 28 Feb 2024
00:30:10 +0000
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Supernus (SUPN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Tue, 27 Feb 2024
23:50:04 +0000
Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates
Supernus (SUPN) delivered earnings and revenue surprises of -95.12% and 6.39%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Tue, 27 Feb 2024
22:00:53 +0000
Supernus Pharmaceuticals Inc (SUPN) Reports Robust Growth in Key Products for Full Year 2023
Qelbree and GOCOVRI Drive Revenue Amidst Legacy Product Declines
Tue, 27 Feb 2024
21:05:00 +0000
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
Fourth quarter 2023 net sales of Qelbree® increased 97% to $46.4 million compared to fourth quarter 2022; Full year 2023 net sales of Qelbree increased 129% to $140.2 million compared to full year 2022.Fourth quarter 2023 net sales of GOCOVRI® increased 10% to $32.0 million compared to fourth quarter 2022; Full year 2023 net sales of GOCOVRI increased 15% to $119.6 million compared to full year 2022.Full year 2023 total revenues (GAAP) were $607.5 million; Full year 2023 total revenues excluding
Mon, 26 Feb 2024
14:15:56 +0000
Ahead of Supernus (SUPN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Supernus (SUPN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Tue, 20 Feb 2024
15:00:48 +0000
Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for
Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tue, 13 Feb 2024
21:05:00 +0000
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
ROCKVILLE, Md., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the fourth quarter and full year of 2023 on Tuesday, February 27, 2024. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call t
Mon, 05 Feb 2024
13:30:00 +0000
Supernus Wins Infringement and Validity Case on Trokendi XR® against Torrent
ROCKVILLE, Md., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the United States District Court for the District of New Jersey ruled that Torrent Pharmaceuticals Ltd. and its subsidiary, Torrent Pharma Inc., infringed U.S. Patent Nos. 8,992,989; 9,549,940; and 9,622,983 by submitting to the U.S. Food and
Sun, 14 Jan 2024
12:36:32 +0000
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?
Most readers would already know that Supernus Pharmaceuticals' (NASDAQ:SUPN) stock increased by 9.4% over the past...
Tue, 19 Dec 2023
12:30:00 +0000
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree® (viloxazine) in Canada
MONTREAL, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive license agreement with Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) ("Supernus"), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, granting Knight the rights to seek regulatory approval and commercialize Q
Fri, 15 Dec 2023
00:43:26 +0000
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
Mental health has been one of the hot topics in the medical industry over the past few years. Widespread awareness was brought to the public eye during the COVID-19 pandemic as people in prolonged lockdowns struggled with isolation as well as the threat of a deadly virus. The World Health Organization has issued statements to emphasize how mental health issues are serious, life-altering conditions not to be downplayed. As a response, various US states raised legislation to legalize psilocybin se
Mon, 04 Dec 2023
17:20:19 +0000
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 8.7% CAGR over the last three years
It hasn't been the best quarter for Supernus Pharmaceuticals, Inc. ( NASDAQ:SUPN ) shareholders, since the share price...
Sat, 18 Nov 2023
10:03:22 +0000
Insider Sell Alert: Director Frederick Hudson Sells 9,093 Shares of Supernus Pharmaceuticals ...
Supernus Pharmaceuticals Inc (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, has recently seen a significant insider sell by one of its directors.
Fri, 10 Nov 2023
17:10:03 +0000
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2023 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2023 Earnings Call Transcript November 8, 2023 Supernus Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.24, expectations were $0.13. Operator: Good afternoon, and welcome to Supernus Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. At this time all participants are in a listen-only mode. Later we will conduct a […]



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "This is one of the brightest and most generous groups you will ever come across. While I firmly believe everyone has something to contribute to the collective wisdom, this is pretty much a left-brain group. Facts, evidence, and reasoned argument will earn you respect, even if some disagree with you." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2024, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards